Showing results (101-110 of 117) with videos related to

Sort By:
Pageof 12
American Heart Journal Plus : Cardiology Research and Practice|December 25, 2025
Cardiac troponin T elevation predicts mortality in hospitalized COVID-19 patientsKatelyn A Bruno, R Scott Wright, Joshua Culberson, et al.
Leukemia & Lymphoma|July 21, 2012
Development and characterization of a novel human Waldenström macroglobulinemia cell line: RPCI-WM1, Roswell Park Cancer Institute - Waldenström Macroglobulinemia 1Kasyapa S Chitta, Aneel Paulus, Sikander Ailawadhi, et al.
Medrxiv : the Preprint Server for Health Sciences|July 9, 2025
Cardiac Troponin T Elevation Predicts Mortality in Hospitalized COVID-19 PatientsKatelyn A Bruno, R Scott Wright, Joshua Culberson, et al.
Blood Cancer Journal|September 1, 2022
Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinibPaul J Hampel, Kari G Rabe, Timothy G Call, et al.
American Journal of Hematology|October 13, 2022
Risk factors for severe infection and mortality In patients with COVID-19 in patients with multiple myeloma and AL amyloidosisMatthew Ho, Saurabh Zanwar, Francis K Buadi, et al.
Mayo Clinic Proceedings|March 15, 2017
Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted TherapyDavid Dingli, Sikander Ailawadhi, P Leif Bergsagel, et al.
Clinical Transplantation|January 8, 2025
Amyloidosis and Heart Transplantation in a New EraMelissa A Lyle, Juan Maria M Farina, Erin Wiedmeier-Nutor, et al.
Mayo Clinic Proceedings|April 2, 2013
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013Joseph R Mikhael, David Dingli, Vivek Roy, et al.
Blood|July 8, 2017
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myelomaJonas Paludo, Joseph R Mikhael, Betsy R LaPlant, et al.
Haematologica|March 5, 2026
Real-world outcomes of newly diagnosed multiple myeloma patients treated with front-line daratumumab bortezomib lenalidomide and dexamethasoneRicardo D Parrondo, Ricardo De Menezes, Hanna Sledge, et al.
Pageof 12